aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2024. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
StageMark develops and markets solutions for identifying and monitoring inflammatory diseases. Their flagship product, CB-CAPs, allows users to analyze complement products bound to various blood cell types, including erythrocytes, platelets, reticulocytes, and lymphocytes. Founded in 2004, StageMark is headquartered in Pittsburgh, Pennsylvania.
StageMark has made significant strides in the medical diagnostics field, providing innovative tools for healthcare professionals to better understand and manage inflammatory conditions. Their impact is reflected in the improved diagnostic capabilities and patient outcomes facilitated by their technology.
Operating Status
Active
Ownership Type(s)
Private
Main Product(s)
Medical Devices
Technology
Biotech
Tags
Healthtech
Model Types
Hardware, Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise, Healthcare
Geographic Exposure
United States
When was StageMark founded?
StageMark was founded in 2004.
Where is StageMark’s headquarters located?
StageMark’s headquarters is located in Pittsburgh, PA, US.
When was StageMark’s last funding round?
StageMark’s most recent funding round was for $1.6M (USD) in April 2007.
How many employees does StageMark have?
StageMark has 30 employees as of Feb 4, 2024.
How much has StageMark raised to-date?
As of July 05, 2023, StageMark has raised a total of $2.4M (USD) since Apr 23, 2007.
Add Comparison
Total Raised to Date
$2.4M
USD
Last Update Apr 23, 2007
Last Deal Details
$1.6M
USD
Apr 23, 2007
Series B
Total Employees Over Time
30
As of Feb 2024
StageMark Address
100 Technology Drive
Suite 400
Pittsburgh,
Pennsylvania
15219
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts